GUANGZHOU, China - TelAve -- POMDOCTOR LIMITED (N A S D A Q: POM) is bringing renewed attention to its artificial intelligence-driven healthcare strategy with a new announcement highlighting the industry's shift from reactive treatment toward predictive and proactive health management. By combining AI, wearable technologies, remote patient monitoring, physician resources and real-world healthcare data, the company is positioning its platform to participate in what could become an important transformation in how chronic conditions are monitored and managed.

Today's announcement reinforces a broader strategy that POMDOCTOR has been developing through a series of recent updates focused on AI optimization, healthcare data commercialization, integrated patient management and expansion of its predictive healthcare infrastructure.

For investors following emerging digital-health companies, the opportunity is compelling: Can POMDOCTOR translate its existing healthcare operations and technology initiatives into a scalable, commercially sustainable platform?

Today's News: Moving Healthcare From "Diagnose and Treat" to "Predict, Alert and Intervene"

In its October 12 announcement, POMDOCTOR outlined its vision for a healthcare model that identifies potential health risks earlier and supports more timely intervention.

Traditional healthcare frequently centers on patients seeking treatment after symptoms emerge. POMDOCTOR believes advances in AI, healthcare data and remote monitoring can help create a more continuous approach, particularly for chronic disease management, where ongoing observation and follow-up can be important.

The company's strategy brings together:

• AI-powered analysis: Using multidimensional healthcare data to help identify potential risk signals and support more informed decisions.
• Wearable technology and remote monitoring: Enabling the collection of health indicators beyond conventional clinical settings.
• Physician-led patient management: Connecting data insights with follow-up and personalized care.
• Real-world healthcare data: Using information gathered over time to support a broader understanding of health trends.

Rather than developing these capabilities in isolation, POMDOCTOR aims to integrate them into a coordinated healthcare management framework. CEO Zhenyang Shi emphasized the company's intention to combine its healthcare operations, physician resources, real-world data and technology capabilities to help build the infrastructure supporting this transition.

The announcement describes the company's strategic direction; it does not establish that predictive outcomes, improved clinical results or commercial returns have already been achieved.

More on TelAve News

• LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
• Security Planning Tips For Your Holiday Event From Access Patrol Services
• Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
• Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
• Kitchen Table Economics: An Invitation to Think Differently

Building on September's AI and Healthcare Data Progress

Today's announcement follows POMDOCTOR's September 30 update detailing continued optimization of its proprietary AI chronic disease management system and progress toward commercializing real-world data capabilities.

The company reported completing multiple rounds of AI system optimization using information that can include medication, diagnosis and treatment, patient behavior, monitoring and healthcare payment data.

Its product roadmap includes risk identification, personalized interventions and physician-patient follow-up workflows. POMDOCTOR also described a feedback process through which information generated during patient management can be used to refine its AI models and support physicians in evaluating health trends.

This approach is designed to move healthcare beyond individual appointments toward continuous, data-driven management.

Another important component is commercialization. POMDOCTOR has identified several areas for developing its real-world data capabilities, including pharmaceutical real-world studies, evidence-based research cooperation, business-to-business healthcare data services and collaborations with third-party healthcare institutions.

The company's September update identified pharmaceutical real-world study and data services as a core value driver within its diversified revenue strategy.

For investors, the central question is whether these initiatives can generate measurable commercial traction, repeat business and sustainable revenue.

A Broader Digital Healthcare Infrastructure Opportunity

POMDOCTOR's longer-term vision extends beyond a single AI application. The company describes a digital healthcare ecosystem combining physician resources, wearable technologies, AI, healthcare payment networks and real-world healthcare data.

The potential appeal is integration. Monitoring technologies can generate information, AI can help analyze it, and physicians can use relevant insights to support patient follow-up. Payment infrastructure and healthcare partnerships could provide additional connections across the service delivery process.

The company has also discussed integrated in-hospital and out-of-hospital chronic disease management pilots, intended to extend monitoring, medication management and physician follow-up beyond individual clinical encounters.

If successfully implemented and commercialized, this coordinated approach could create opportunities across patient management and healthcare research.

However, investors should distinguish the strategic opportunity from demonstrated results. The company's announcements do not, by themselves, establish the scale of future revenue, customer adoption, profitability or the timing of commercialization.

Recent Developments Investors Should Know

POMDOCTOR's latest announcement follows several developments that help frame the company's evolving strategy:

• September 30, 2026: The company reported further AI chronic disease management system optimization, expanding real-world data applications and advancing integrated care pilots.
• September 2026: POMDOCTOR announced participation in the H.C. Wainwright 28th Annual Global Investment Conference, providing an opportunity to present its strategy to the investment community.
• August 2026: The company highlighted its healthcare intelligence flywheel and diversified revenue structure in separate announcements, emphasizing the intended relationship between healthcare operations, data and commercial services.
• July 2026: POMDOCTOR outlined its healthcare data asset strategy as part of its efforts to strengthen AI-powered chronic disease management.

Together, these updates show a consistent strategic direction: connect healthcare delivery, AI capabilities and data-related services within a broader predictive healthcare platform.

More on TelAve News

• Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
• CB Stuffer Announces Private Sale to Secure Future of Brand Growth
• The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
• Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
• Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition

A Critical Investor Risk: Nasdaq Delisting Determination

While POMDOCTOR's technology strategy provides a developing business narrative, investors must also consider a significant listing-related challenge.

On October 9, the company announced that Nasdaq had issued a staff delisting determination after its American depositary shares closed below the $1.00 minimum bid-price requirement for 30 consecutive business days, from August 24 through October 5, 2026.

The company explained that its June 22, 2026, one-for-18 reverse stock split made it ineligible for the ordinary 180-calendar-day compliance period under the applicable Nasdaq rules.

POMDOCTOR stated that it intended to request a hearing to appeal the determination and present a plan to regain compliance. The stated deadline was October 13, 2026. A timely hearing request would stay the suspension and related delisting process while the appeal remains pending.

The outcome is not assured. The company has cautioned that there can be no guarantee that the hearing panel will grant additional time, that POM will regain compliance or that the appeal will succeed.

This issue is a material near-term consideration for shareholders and prospective investors, independent of the company's longer-term technology opportunity.

What Comes Next for N A S D A Q: $POM?

Looking ahead, investors will want to monitor several developments:

• Further AI system development and evidence of practical deployment.
• Commercial traction in pharmaceutical real-world studies and healthcare data services.
• Progress in integrated chronic disease management pilots.
• Evidence of customer adoption, revenue growth and sustainable business execution.
• The outcome of POMDOCTOR's Nasdaq appeal and its ability to satisfy continued listing requirements.

The Bottom Line

POMDOCTOR LIMITED is pursuing an ambitious opportunity at the intersection of artificial intelligence, chronic disease management, wearable technology and real-world healthcare data. Today's October 12 announcement reinforces management's vision of a more predictive and proactive healthcare model, while September's updates provide additional context for the company's technology development and commercialization priorities.

For more information on POM visit:  https://ir.7shiliu.com/

Media Contact
Company Name: POMDOCTOR Limited (N A S D A Q: POM)
Contact Person: Zhenyang Shi, Chairman and Chief Executive Officer
Email:  ir@7lk.com
Phone: 86 020-6231 2277
Country: China

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website